People with multiple myeloma are prone to experience significant workplace and functional impairment, high out of pocket costs, and frequent office visits, researchers concluded after conducting a cross-sectional study involving 162 individuals. Adherence to therapy can blunt the impact. Participants with multiple myeloma were divided into 2 groups according to their medication adherence scores. They completed 3 surveys, including the Functional Assessment of Cancer Therapy–Multiple Myeloma (FACT-MM): Among the results:
- FACT-MM scores averaged 98.5.
- Absenteeism and presenteeism averaged 18% and 52%, respectively.
- Work productivity and activity impairment averaged 57% and 50%, respectively.
- Out-of-pocket costs averaged ~$700 in the prior 3 months.
- Patients spent an average of ~7 hours in monthly appointments with clinicians.
- Patients with high medication adherence had higher FACT-MM scores.
- Those with lower medication adherence reported greater activity impairment and were more apt to be overwhelmed/frustrated with appointment rescheduling.
Gupta S, Abouzaid S, Liebert R, Parikh K, Ung B, Rosenberg A. Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma. [Published online ahead of print February 3, 2018]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2018.01.006.
This Week's Must Reads
Widespread Zika screens not cost effective, Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977
New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.
Good ALL outcomes in Down syndrome children, Maloney K et al. ASPHO 2018, annual meeting of the American Society of Pediatric Hematology/Oncology Abstract PP 2001
Reducing morbidity in postpartum hemorrhage, Smith R et al. Annual clinical and scientific meeting of the American Society of Obstetricians and Gynecologists 2018, Abstract 26R.
In sickle cell, start hydroxyurea in infancy, Schuchard S et al. ASPHO 2018, poster # 342 Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057
Must Reads in Myelodysplastic Syndrome
Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126 https://doi.org/10.1016/S2352-3026(18)30016-4
Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al
Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al
This Predicts Risk of Early Relapse, Death in MM , Biol Blood Marrow Transplant; ePub 2018 Feb 23; Cowan, et al
Undertreatment of Newly-Diagnosed MM Evaluated, Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al